Here's why pharma giant AbbVie coughed up $10 billion to buy a startup you've never heard of

AbbVie, a major biopharmaceutical company, just picked up biotech startup Stemcentrx in a deal that’s worth up to $10.2 billion.That would make it the second-largest venture capital-backed acquisition in history. The startup, which had previously been valued at $5 billion, is developing drugs that target cancer stem cells, a specific type of cancer cell that some research suggests could play a key role in defeating the disease.

http://www.businessinsider.com.au